The magnitude of SP rise will depend primarily on interest...

The magnitude of SP rise will depend primarily on interest generated overseas - both medically and investor. These approvals will allow direct sales into Europe and US without the need for phase 2 and 3 trials - if the results from such use look good there will potentially be a steep uptake by clinicians. The company will still need proper trials especially to enable government subsidisation such as PBS scheme but people with pancreatic (and liver) cancer - and their clinicians - want to try every possible option to live longer and comfortably. Uptake with such treatment can be extremely fast due to the population of patients.
If this treatment really stands up to the rigors of clinical use and shows definite advantage the SP will be up many magnitudes. Getting the license to sell is step one and pretty exciting.

Tyremen